CGS Administrators Aligns LCD for DermTech Pigmented Lesion Assay With Palmetto

CGS Administrators, a Medicare Administrative Contractor that participates in the MolDx program, released its final local coverage determination for DermTech’s Pigmented Lesion Assay (PLA).

CGS’s decision aligns with Palmetto GBA’s previously announced coverage determination for the test. The contractors will cover the non-invasive RNA gene expression test to rule out primary cutaneous melanoma and to help decide if patients with melanocytic skin lesions that display one of more clinical characteristics suggestive of melanoma should be biopsied.

Source: https://www.genomeweb.com/reimbursement-news/cgs-administrators-aligns-lcd-dermtech-pigmented-lesion-assay-palmetto